#None #therapies #Treatment Resistant Hypertension #TTRYVIO

Understanding the Treatment Resistant Hypertension Market

Overview

The treatment resistant hypertension (TRH) market is poised for significant growth, projected at a CAGR of 5% from 2020 to 2034, driven by enhanced diagnosis and treatment for patients suffering from this condition. Rise in awareness about hypertension, advancements in diagnostic practices, and the development of innovative therapeutic options are key factors contributing to this growth. DelveInsight's recent report on the TRH market provides comprehensive insights into treatment practices, emerging therapies, and market size across key regions including the United States, EU4, the UK, and Japan.

Current Landscape of Treatment Resistant Hypertension

Resistant hypertension refers to cases where blood pressure remains elevated despite the use of at least three antihypertensive medications, including a diuretic. In 2024, the number of diagnosed cases in the seven major markets (7MM) was approximately 13 million, with the United States leading due to its aging population and increasing awareness about managing hypertension. Notably, the diagnosed prevalence of TRH varies between 10–14% across the 7MM, emphasizing the significant burden of this condition.

Clinical Management Strategies

The management of resistant hypertension typically combines both pharmacological and lifestyle interventions:

• - Initial Pharmacological Treatment: The standard approach includes a combination of an ACE inhibitor or ARB, a calcium channel blocker, and a long-acting thiazide diuretic. If blood pressure remains uncontrolled, spironolactone is generally introduced as the fourth-line treatment.
• - Lifestyle Modifications: Significant lifestyle changes, such as regular exercise, weight management, reduced salt intake, and smoking cessation, play a crucial role in controlling blood pressure levels.

Innovative Therapies

The recent introduction of novel therapies is set to transform the treatment landscape. Notably, TRYVIO (aprocitentan), recently approved by both the FDA and EMA, is recognized as the first new class of antihypertensive drug in nearly 40 years. It works by inhibiting endothelin receptors, providing a fresh avenue for managing resistant hypertension. Following TRYVIO, other innovative therapies such as Baxdrostat and Lorundrostat are expected to enter the market by 2026, which could further enhance treatment efficacy for patients.

Future Projected Trends

The anticipated market size for TRH is estimated at USD 6.8 billion in 2024, driven by the launch of new therapies and an increase in device-based treatments. Companies such as AstraZeneca, Mineralys Therapeutics, and Idorsia are at the forefront of developing these emerging therapies, promising more effective solutions for patients with resistant hypertension.

Market Dynamics and Challenges

While the TRH market is expanding, several challenges need to be addressed. Complex medication regimens combined with lifestyle changes can lead to patient non-adherence. Additionally, not all patients respond positively to existing therapies, highlighting the necessity for the continuous development of alternative treatment options. Regulatory hurdles, reimbursement issues, and the significant costs associated with treatment also present obstacles that could impede market growth.

Nevertheless, the ongoing innovations and increased adoption of personalized medicine approaches are likely to enhance patient care in the coming years, shaping a more effective and accessible treatment landscape for resistant hypertension.

Conclusion

As awareness and treatment options for resistant hypertension improve, the market is expected to evolve dynamically. Continued investment in research and innovative drug development will be pivotal in addressing the growing burden of TRH worldwide, ultimately enhancing patient outcomes and quality of life. With emerging therapies set to reshape the treatment approaches, the future of the resistant hypertension market appears promising.